Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6-Month Open-Label Extension Study of Armodafinil as Adjunctive Therapy in Bipolar I Depression
2009-016648-38Phase 3Completed
- Sponsor
- Cephalon, Inc.
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of armodafinil in bipolar I disorder, sponsored by Cephalon, Inc. Primary endpoints: Primary safety and tolerability and Efficacy outcomes. Started Jun 2010; status: completed.
02
Drugs
armodafinil
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2009-016648-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016648-38.